Ovarian cancer: time to move beyond one size fits all.
Publication
, Journal Article
Secord, AA
Published in: Lancet Oncol
June 2019
Duke Scholars
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
June 2019
Volume
20
Issue
6
Start / End Page
754 / 755
Location
England
Related Subject Headings
- Recombinant Fusion Proteins
- Paclitaxel
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- Double-Blind Method
- Carboplatin
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A. (2019). Ovarian cancer: time to move beyond one size fits all. Lancet Oncol, 20(6), 754–755. https://doi.org/10.1016/S1470-2045(19)30285-2
Secord, Angeles Alvarez. “Ovarian cancer: time to move beyond one size fits all.” Lancet Oncol 20, no. 6 (June 2019): 754–55. https://doi.org/10.1016/S1470-2045(19)30285-2.
Secord AA. Ovarian cancer: time to move beyond one size fits all. Lancet Oncol. 2019 Jun;20(6):754–5.
Secord, Angeles Alvarez. “Ovarian cancer: time to move beyond one size fits all.” Lancet Oncol, vol. 20, no. 6, June 2019, pp. 754–55. Pubmed, doi:10.1016/S1470-2045(19)30285-2.
Secord AA. Ovarian cancer: time to move beyond one size fits all. Lancet Oncol. 2019 Jun;20(6):754–755.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
June 2019
Volume
20
Issue
6
Start / End Page
754 / 755
Location
England
Related Subject Headings
- Recombinant Fusion Proteins
- Paclitaxel
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- Double-Blind Method
- Carboplatin
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis